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Abstract
Background—Intestinal microbiota influences the progression of colitis-associated colorectal 
cancer (CAC). With diet being a key determinant of the gut microbial ecology, dietary 
interventions are an attractive avenue for the prevention of CAC. Curcumin is the most active 
constituent of the ground rhizome of the Curcuma Longa plant, which has been demonstrated to 
have anti-inflammatory, anti-oxidative and anti-proliferative properties.
Methods—Il10−/− mice on 129/SvEv background were used as a model of CAC. Starting at 10 
weeks of age, WT or Il10−/− mice received six weekly i.p. injections of azoxymethane (AOM) or 
saline, and were started on either a control or curcumin-supplemented diet. Stools were collected 
every 4 weeks for microbial community analysis. Mice were sacrificed at 30 weeks of age.
Results—Curcumin-supplemented diet increased survival, decreased colon weight/length ratio, 
and at 0.5%, entirely eliminated tumor burden. Although colonic histology indicated improvement 
with curcumin, no effects of mucosal immune responses have been observed in PBS/Il10−/− mice, 
and limited effects were seen in AOM/Il10−/− mice. In WT and in Il10−/− mice, curcumin 
increased bacterial richness, prevented age-related decrease in alpha diversity, increased the 
relative abundance of Lactobacillales, and decreased Coriobacterales order. Taxonomic profile of 
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AOM/Il10−/− mice receiving curcumin was more similar to those of wild-type mice than those fed 
control diet.
Conclusions—In AOM/Il10−/− model, curcumin reduced or eliminated colonic tumor burden 
with limited effects on mucosal immune responses. The beneficial effect of curcumin on 
tumorigenesis was associated with the maintenance of a more diverse colonic microbial ecology.
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INTRODUCTION
Colorectal cancer (CRC) is the third highest cause of cancer-related mortality in the U.S.A. 
It is estimated that 93,090 people will be diagnosed with colon cancer, 39,610 with rectal 
cancer, and 49,700 will die from CRC in 2015 in the US alone. 1 Worldwide, CRC is the 
fourth most common cancer cause of death, accounting for roughly 1.2 million new cases 
and 600,000 deaths per year.2 Genetic predispositions underlie the pathogenesis of less than 
5% of CRC cases, mostly in Lynch syndrome [mutations in the mismatch repair pathway 
(MMR)], in hereditary non-polyposis colorectal cancer (HNPCC), familial adenomatous 
polyposis (FAP), and MYH-associated polyposis (MAP). The vast majority of CRC cases, 
estimated at over 95%, are sporadic cancers occurring in individuals without inheritable 
predisposition to the disease.3 Environmental factors, inflammation, and gut microbiota 
have been implicated in the pathogenesis of cancer initiation and the progression from a 
hyper-proliferative state, through adenoma formation, to progression to carcinoma.
The current concept that the inflammatory microenvironment represents a risk factor for 
cancer development dates back to the early observations of inflammatory infiltrates within 
neoplastic lesions by Rudolf Virchov.4 In the case of CRC, the effects of chronic 
inflammation on cancer are well exemplified in Inflammatory Bowel Diseases (IBD). 
Crohn’s disease (CD) and ulcerative colitis (UC) are both associated with increased cancer 
risk 5, with duration and severity of chronic colitis conferring significant risk factors for 
colitis-associated colon cancer (CAC).6–8 Although the etiology of IBD still remains 
incompletely understood, animal model-based studies indicate that the host intestinal 
microbiota triggers and/or perpetuates an immune response required for the onset and 
progression of the disease. Next generation sequencing approaches have elucidated profound 
changes in gut microbial ecology in IBD patients and in mouse models, although 
demonstrating the causality and the mechanisms involved still remain a challenge.9 
Intestinal microbiota is also a target of inflammation that affects the development and 
progression of CAC.10 Recent evidence from a gnotobiotic Il10−/− mouse model indicates 
that colitis is not sufficient to promote CAC and requires the presence or expansion of a 
more specific pathobiont, i.e. a symbiont that is able to promote pathology only when host’s 
specific genetic or environmental conditions are altered.11
Currently, three theories are proposed to explain the microbial influence on colon cancer 
development: a model in which the pathogenesis is driven by selected pathobiont(s); a 
model in which global changes to the microbial ecology support carcinogenesis; and a 
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model which combines pathobiont(s) interacting with a changing microbial community.12 T-
bet−/−xRag−/− Ulcerative Colitis (TRUC) mice13 provide an example, which supports the 
latter model. In TRUC mice, the combination of Klebsiella pneumoniae and Proteus 
mirabilis potently induced colitis in conventionally housed, but not in germ-free animals. 
This suggested a dependence on the interaction of these two bacterial species with the 
commensal microbiota community to induce disease.13 The interplay of one or more 
specific bacterial species with the entire commensal bacterial community to drive disease 
development highlights the importance global changes in microbial gut ecology. It also 
suggests that therapeutic approaches with the potential to restore its diversity and normalize 
the composition of the colonic microbial community would be highly desirable.
Curcumin (diferuloyl-methane), a bioactive component derived from a rhizome of the 
Curcuma longa plant, has been demonstrated to function as an antiseptic, analgesic, anti-
inflammatory, antioxidant, chemopreventive, chemo- and radio-sensitizing agent14–16. Our 
laboratory has extensively studied the anti-inflammatory benefits of curcumin in murine 
IBD models.17–19 More recently, we also demonstrated that curcumin inhibits colon cancer 
cell migration through physical interaction with and activation of PTPN1 tyrosine 
phosphatase to reduce the abnormally hyperphosphorylated and hyperactive form of 
cortactin, a protein implicated in cancer motility and tumor invasiveness. 20 We 
hypothesized that due to its poor bioavailability, orally administered curcumin as a dietary 
supplement targets and impacts primarily epithelial cells and the gut microbiota, and that 
curcumin may modulate colonic microbial ecology and prevent the progression of chronic 
colitis to CAC. Although preventive treatment with curcumin in AOM/DSS model of CAC 
was shown to be effective,21 chemopreventive effects of curcumin in established immune-
mediated colitis and its association with colonic microbiota has not been previously 
investigated. In this report, we demonstrate that in a model of AOM-induced colon cancer in 
conventionally housed Il10−/− mice, dietary curcumin dose-dependently reduced or entirely 
prevented colon cancer development. These chemopreventive effects appeared unrelated to 
the reduction of inflammation, but rather to the normalizing effects of curcumin on colonic 
microbial ecology, thus suggesting that curcumin functions as an effective agent for 
restoring healthy gut homeostasis and microbial-host relationship.
METHODS
Experimental animals
Specific pathogen-free wild type (WT) 129/SvEv mice and germ-free Il10−/− mice on the 
same genetic background were originally obtained from the National Gnotobiotic Rodent 
Resource Center at the University of North Carolina, Chapel Hill, re-derived through 
embryo transfer, and transferred to a conventional animal facility at the University of 
Arizona Health Sciences Center. Sentinel mice were routinely monitored and determined as 
free from common murine pathogens (MHV, MPV, MVM, TMEV, Mycoplasma pulmonis, 
Sendai, EDIM, MNV, ecto- and endoparasites). All animal protocols and procedures were 
approved by the University of Arizona Animal Care and Use Committee.
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98.05% pure curcumin, free of contaminating curcuminoids (demethoxy-curcumin and bis-
demethoxy-curcumin) was obtained from ChromaDex (Irvine, CA). Curcumin was 
incorporated into NIH-31 modified open formula (base composition listed under the 
following Link) at 0.05, 0.1, 0.5 and 1% and pelleted by Harlan Teklad (Madison, WI). 
Based on the average chow intake, the calculated human equivalency dose (HED) of 
curcumin ranged from 8 mg/kg/day – 162 mg/kg/day, for 0.05% and 1% diets, respectively, 
and were within the range of well tolerated doses reported by phase I human trials.22, 23 
Control diet without curcumin supplementation was processed in parallel. Diets were 
vacuum-packed in small portions and kept at −20°C until needed.
AOM/Il10−/− model of CAC and experimental groups
We utilized a well-documented model to study the development of colitis-associated colon 
cancers in IL-10-deficient mice. 24, 25 This protocol is based on the use of the mutagenic 
agent, AOM, which exerts colonotropic carcinogenicity. WT and Il10−/− mice on 129/SvEv 
genetic background reared and housed in the same room were allowed to age to 10 weeks by 
which point the Il10−/− mice develop spontaneous and progressive colitis.26, 27 Il10−/− mice 
entering the study were prescreened by ELISA for systemic marker of inflammation, serum 
amyloid A to ensure established colitis. 60 WT and 60 Il10−/− mice were assigned into PBS 
vs. AOM groups, and into respective dietary groups (6 mice per treatment/diet group). Six 
intraperitoneal injections of AOM (10mg/kg) were administered weekly to initiate 
tumorigenesis. Mice were monitored for another 14 weeks, and sacrificed at the age of 30 
weeks (Fig. 1A) at which time tissues were harvested for histopathological and biochemical 
analyses.
Histology and scoring
Colons from WT and Il10−/− mice on different curcumin diets were harvested, Swiss-rolled, 
and fixed in 10% neutral buffered formalin (Fisher Scientific, Tustin, CA). Fixed tissues 
were then embedded in paraffin, and 5-μm-thick tissue cuts were stained with hematoxylin 
and eosin (H&E) for light microscopic examination. Sections were graded by a veterinary 
pathologist blinded to the study design according to previously published criteria28.
Immunohistochemistry
Immunohistochemical labeling (IHC) of β-catenin was performed with a rabbit monoclonal 
antibody (clone E247; AbCam). Ki67 IHC was performed using a rabbit polyclonal antibody 
(#NCL-Ki67p, Leica Biosystems GmbH, Nussloch, Germany). Tissue sections were stained 
with a Discovery XT Automated Immunostainer (VMSI; Ventana Medical Systems, Inc., 
Tucson, AZ; VMSI) using VMSI-validated reagents for deparaffinization, cell conditioning 
(antigen retrieval with a borate-EDTA buffer), primary antibody staining, detection and 
amplification using a biotinylated-streptavidin-HRP and diaminobenzidine (DAB) system 
and hematoxylin counterstaining. Following staining, slides were dehydrated through graded 
alcohols to xylene and coverslipped with mounting medium.
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Images were captured using an Zeiss Axioplan microscope (Carl Zeiss MicroImaging, 
Thornwood, NY) using Nikon Digital Sight DS-Fi1 camera and NIS-Element software 
(Nikon Instruments, Melville, NY). All images were standardized for light intensity and 
white balance. Expression of Ki67 and β-catenin in the colonic epithelial cells was evaluated 
by two independent and unbiased investigators. Ki67-positive cells were counted per 3–5 
high-powered fields and expressed as mean +/− SEM in respective groups. β-catenin was 
evaluated in a similar manner and was expressed as percentage of epithelial cells with 
exclusively basolateral membrane staining or mixed cytoplasmic/nuclear staining.
Real-time RT-PCR
Real-time RT-PCR was used to evaluate mucosal expression of TNF-α, IFNγ, IL-6, IL-1β, 
IL-17A, IL-12p40, IL-23 mRNA. Total RNA was isolated from mouse distal colon using 
TRIzol reagent (Invitrogen, Carlsbad, CA). 250ng of total RNA was reverse-transcribed 
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Subsequently, 20 μl of the PCR 
reactions were set up in 96-well plates containing 10 μl 2x IQ Supermix (Bio-Rad), 1 μl 
TaqMan® primer/probe set (ABI, Foster City, CA), 2 μl of the cDNA synthesis reaction 
(10% of RT reaction) and 7 μl of nuclease-free water. Reactions were run and analyzed on a 
Bio-Rad iCycler iQ real–time PCR detection system. Data were analyzed by using the 
comparative Ct method as means of relative quantification, normalized to an endogenous 
reference (TATA Box Bonding Protein, TBP or glyceraldehyde 3-phosphate dehydrogenase, 
GAPDH) and relative to a calibrator (normalized Ct value obtained from control mice) and 
expressed as 2−ΔΔCt (Applied Biosystems User Bulletin #2: Rev B “Relative Quantification 
of Gene Expression”).
Bacterial DNA processing
Fecal samples were collected fresh once per month from individual mice directly into sterile 
Eppendorf tubes and stored at −80°C until processing. For processing, frozen stool samples 
were individually placed into an Eppendorf tube containing autoclaved zirconium beads, 
lysis buffer (100mM NaCl, 10mM Tris, 100mM EDTA and 0.2mg/ml Proteinase K) and a 
solution of 20% DNAse-free SDS (Sodium dodecyl sulfate) and incubated for 2 hours. The 
samples were then mixed with 24:24:1 Phenol:Chloroform:IAA (pH 8.0) and placed into an 
automatic bead beater machine on high settings for 2 min. Samples were centrifuged (8,000 
rpm for 3 min.) and the aqueous phase was collected and mixed again with 1:1 
Phenol:Chloroform and centrifuged (13,000 rpm, 3 min). The aqueous phase was collected, 
mixed with −20°C isopropanol and 3M sodium acetate (1:10 ratio), and incubated at 4°C for 
20 min. DNA was precipitated by centrifugation (13,000 rpm for 20 min. at 4°C) and excess 
supernatant was discarded. The remaining pellets were washed with cold (4°C) 100% 
molecular grade ethanol and centrifuged (13,000 rpm for 5 min. at 4°C). Excess supernatant 
was discarded and the remaining pelleted material was allowed to air-dry and was then re-
suspended in TE (Tris-EDTA, pH 8.0) buffer.
Generation of 16S amplicon library, MiSeq sequencing, and QIIME analysis of microbial 
gut ecology
The V4 hypervariable region of the 16S rRNA gene was amplified using barcoded PCR with 
515F and 806R primers following the Earth Microbiome Project protocol29 and quantified 
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using Nanodrop. Sequencing was performed at Argonne National Laboratories on an 
Illumina MiSeq (Serial # M02149) using the MCS (MiSeq Control Software) version 2.2.0. 
540μL of 6.75pM 16S amplicon library with 597 pooled samples were mixed with 6.75pM 
PhiX control DNA (10% final), and sequenced in one run, with 17,278,176 total sequences 
(5′ reads) generated. The raw sequence data was de-multiplexed using QIIME 1.8.0 30 and 
assigned to sample IDs using QIIME’s default quality filtering process.31 After quality 
filtering 10,244,883 reads remained. The remaining reads had a median length of 151 bases.
Sequences were assigned to clusters of 97% similarity using QIIME’s uclust-based32 open-
reference operational taxonomic unit (OTU) picking protocol33 against the Greengenes 13_5 
reference sequence set34. The centroid of each OTU was chosen as the representative 
sequence for the OTU. The representative sequences were aligned with PyNast35 and the 
trees were constructed with FastTree36 for phylogenetic calculations. The average number of 
sequences per sample was 17,160.6 ± 5,944.6 (mean ± SD). After quality filtering and open 
reference picking, the minimum number of sequences in a given sample in order to retain a 
sample in the study was set to 6,000. This resulted in the exclusion of 18 samples that 
contained fewer than 6000 reads.
Beta-diversity calculations were performed using weighted and unweighted-unifrac 
metrics37 with exactly 6,000 randomly selected sequences per sample using rarefaction as 
implemented in QIIME. Alpha diversity metrics were calculated using phylogenetic 
diversity38,39 (a phylogenetic richeness metric) as implemented in QIIME and using 
Margalef’s diversity index in Excel.
Statistical significance for differences in alpha diversity was determined by nonparametric 
analysis of variance (ANOVA) tests comparing the alpha diversity results across grouped 
samples. Statistical significance for differences in beta diversity across sample groups was 
calculated using ANOSIM (Analysis of Similarity) with 1000 permutations. The Bonferroni-
corrected Kroskal-Wallis test was used for to test for differentially abundant OTUs across 
sample groups.
Prediction of metagenome functional content from the 16S rRNA marker gene was done 
using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt),40 using PICRUSt’s Kyoto Encyclopedia of Genes and Genomes (KEGG) gene 
annotation database. This was done by first picking OTUs against 13 August 2013 
Greengenes database for compatibility with PICRUSt. The resulting BIOM file was 
uploaded into the online Galaxy PICRUSt server (http://huttenhower.sph.harvard.edu/
galaxy/) for metagenome prediction. The predicted metagenome BIOM file was further 
analyzed using Statistical Analysis of Metagenomic Profiles (STAMP) software package41, 
using ANOVA and Tukey-Kramer post-hoc test.
All sequence data generated in this study will be available in Qiita (formerly called the 
QIIME DB) upon acceptance of the manuscript.
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Statistical analysis of non-microbiome data
Normality of data distribution was tested by Shapiro-Wilk test. If normality was confirmed, 
statistical significance was determined by the factorial analysis of variance (ANOVA) with 
three main effects (diet, genotype, and/or PBS/AOM groups) followed by the Fisher PLSD 
post-hoc test with StatView software package v.4.53 (SAS Institute, Cary, NC). In instances 
where normality test failed (selected groups in histological scoring analysis), Kruskal-Wallis 
One Way ANOVA on Ranks was employed followed by Dunn’s T test. Where appropriate, 
unpaired two-tailed T test was used using Excel software. Data were expressed as mean +/− 
standard error of mean.
RESULTS
Curcumin (0.5%) prevents mortality and improves body weight gain in AOM/Il10−/− mice
We first determined the effect of curcumin on survival and body weight of AOM/Il10−/− 
mice following a treatment intervention (Fig. 1A). No mortality was observed in WT mice 
fed curcumin-supplemented diets. One of six Il10−/− mice injected with PBS and fed control 
diet died before the conclusion of the study. No mortality was observed in chronically 
inflamed Il10−/− mice injected with PBS and fed curcumin-supplemented diets (Fig. 1B). 
While 50% mortality was observed in AOM/Il10−/− mice fed control diet, 100% survival 
was noticed in AOM/Il10−/− mice exposed to 0.5% curcumin diet (Fig. 1C). However, 1% 
curcumin resulted in increased mortality in both AOM/WT and AOM/Il10−/− mice, 
therefore these groups were removed from the study. In PBS-treated WT mice, 0.5% 
curcumin diet tended to result in transient body weight decrease (Fig. S1A), consistent with 
the previously reported lower food consumption.17 While PBS-injected WT mice on control 
diet steadily gained weight during the study, similarly treated Il10−/− mice failed to accrue 
body weight (Fig. S1A). Interestingly, in PBS-treated Il10−/− mice, 0.5% curcumin not only 
did not improve, but led to a gradual and significant loss of body weight (Fig. S1A). 
However, in AOM-treated groups, curcumin entirely prevented body weight loss in Il10−/− 
mice, which was indistinguishable from AOM-treated WT mice on control diet (Fig. S1B).
Curcumin reduced hyperplasia in AOM-treated Il10−/− mice
Colon weight/length ratio is a widely used marker of mucosal hyperplasia in chronic colitis, 
which corresponds well to histological scoring.42 Dietary curcumin dose-dependently 
reduced weight/length ratio in both Il10−/−/PBS (without reaching statistical significance; 
ANOVA p=0.15), in WT/AOM, and especially in AOM/Il10−/− groups (p<0.05; Fig. 2A). 
Analysis of Ki67+ proliferating epithelial cells in the distal colon (primary site of AOM-
induced tumorigenesis) was assessed in areas free of frank and histologically confirmed 
tumors. It showed a modest trend in curcumin-mediated reduction in the numbers of actively 
proliferating epithelial cells (Fig. 2B,C). This finding implies that in our model, the effects 
of curcumin on the colonic weight/length ratio was likely secondary to decreased edema and 
reduced thickness of the smooth muscle layers rather than direct generalized effect on 
epithelial cell proliferation.
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Curcumin reduced tumor burden in AOM-treated Il10−/− mice
We assessed the occurrence of colonic tumors in PBS- and AOM-treated mice and whether 
dietary curcumin affects CAC development. PBS-treated WT mice fed control or 
supplemented diets had no spontaneous macro- or microscopic tumors. AOM-treated 
Il10−/− mice showed more than 3-fold higher number of macroscopic lesions predominantly 
localized in the distal colon, characteristic of the model (Fig. 3A).43 Curcumin dose-
dependently reduced tumor burden in AOM/Il10−/− mice, with the 0.5% dosage entirely 
eliminating all macroscopic lesions (Fig. 3A). Microscopic evaluation of tissue sections 
closely correlated with the results presented in Fig. 3A (not shown). Figure 3B depicts 
representative photograph of distal colon of AOM-treated Il10−/− mice on control or 0.5% 
curcumin diet. No lesions were observed in AOM-treated WT mice exposed to curcumin at 
any of the three doses used.
Curcumin reduced aberrant localization of β-catenin in AOM-treated Il10−/− mice
We next evaluated the general expression and localization of β-catenin, a protein involved in 
cell-cell adhesion, gene transcription, cellular proliferation and differentiation, and which is 
commonly mutated in colon cancer.44 In PBS-treated WT and Il10−/− mice, β-catenin was 
almost exclusively localized to the plasma membrane, and it was not affected by curcumin-
supplemented diet (Fig. 4A). In AOM-treated WT mice on control diet, we observed mucin-
depleted crypt foci with aberrant cytoplasmic and nuclear localization of β-catenin (Fig. 4B). 
0.5% curcumin restored β-catenin expression pattern to that observed in PBS-treated WT 
mice on control diet (Fig. 4B). In AOM-treated Il10−/− mice, analysis of mucosal section 
outside of frank tumors (absent in 0.5% curcumin-treated mice) showed inflammatory 
lesions with disorganized crypts with mixed focal mucin-depleted lesions with 
predominantly cytoplasmic and nuclear localization of β-catenin (Fig. 4B). Striking 
normalization of β-catenin staining was observed in AOM-treated Il10−/− mice fed 0.5% 
curcumin diet (Fig. 4B).
Curcumin has limited anti-inflammatory effects in PBS- or AOM-injected Il10−/− with 
established colitis
Inflammation is an important risk factor for CRC development and we next investigated 
whether curcumin-mediated decreased in carcinogenesis was linked to the inflammatory 
status of AOM/Il10−/− mice. In mice fed control diets, histological scores in the proximal 
and distal colon were significantly higher in both PBS-injected and in AOM-injected Il10−/− 
mice as compared to WT mice (Fig. 5). Curcumin did not significantly impact colonic 
inflammation in either segment in PBS-injected Il10−/− mice, thus suggesting that in the 
settings of established colitis, curcumin has limited anti-inflammatory potential in any of the 
three doses analyzed (Fig. 5A,B). In curcumin-treated AOM-injected WT and Il10−/− mice, 
we observed a trend toward improvement in inflammatory score, albeit without reaching 
statistical significance (Fig. 5A). In the distal colon of AOM-treated Il10−/− mice, 0.5% 
curcumin significantly decreased histological score (Fig. 5B). Representative images of 
H&E-stained tissues of AOM-treated mice are depicted in Figure 5C. This improvement in 
histological inflammation appeared to be largely driven by decreased hyperplasia, reduced 
submucosal edema and smooth muscle thickness, and not by suppression of mucosal 
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immune responses. Curcumin treatment was not associated with statistically significant 
decreases in mucosal cytokine expression in the proximal colon of either PBS- or AOM-
treated Il10−/− mice (Fig. 5D, Suppl. Fig. S2). Although in the distal segment, curcumin 
reduced the mucosal expression of IL-6, IL-1β, IL-17A, and IL-23p19 in PBS-injected 
Il10−/− mice, it remained without statistically significant effect in AOM-injected Il10−/− 
mice (Fig. 5D, Suppl. Fig. S2). These findings suggested that despite the overall 
improvement in the colonic mucosal architecture, curcumin-mediated strong decreased 
carcinogenesis was not primarily due to a significant decrease in mucosal immune responses 
in AOM/Il10−/− mice.
Microbial analysis of the effect of curcumin-supplemented diet
A non-parametric ANOSIM (Analysis of Similarity) method showed that among single 
variables, mouse gender or diet (all doses considered) were not significantly different based 
on a unifrac beta diversity metric (Supplemental Table 1). However, because of the striking 
reduction of tumor burden in mice receiving 0.5% curcumin diet and modest effect on 
inflammation, we further investigated whether curcumin primary effect was associated with 
a change in microbial diversity. We first assessed whether curcumin at the most efficacious 
dietary concentration (0.5%) had a long-term effect on colonic luminal microbial 
composition in healthy mice. WT mice fed control diet showed age-dependent reduction in 
species richness between 10th and 30th week of age (810.3 ± 20.9 vs. 652.8 ± 116.1; p<0.05) 
and in Margalef index (93.0 ± 1.2 vs. 74.9 ± 13.3; p<0.05). Interestingly, WT/PBS mice 
switched to 0.5% curcumin-supplemented diet at 10 weeks of age maintained high diversity 
until 30 weeks of life, expressed both as the number of observed species (735.9 ± 28.7 and 
738.2 ± 63.2, 10 weeks vs. 30 weeks, respectively; p=0.97) or as the Margalef index (84.48 
± 3.2 and 84.74 ± 7.27, 10 weeks vs. 30 weeks, respectively; p=0.97). At the taxonomic 
level, to increase the statistical power, we used repeated-measures non-parametric Friedman 
test to compare fecal microbial ecology in WT PBS-injected control mice at the time of diet 
switch (10 weeks), and 8 weeks and 16 weeks into the period of 0.5% curcumin diet (18 and 
26 weeks of age). As a control for age-related changes, we analyzed WT/PBS mice fed 
control diet throughout this period. The taxonomic analysis (relative abundances) at the 
order level was performed with 16 orders comprising >99.9% of OTU’s at this level. We 
observed gradual increase in the relative abundance of Lactobacillales (represented mainly 
by genus Lactobacillus), gradual loss of Coriobacteriales (Actinobacteria phylum) (Fig. 6A) 
and a transient increase (at 18 weeks of age) in the putative order YS2 (Cyanobacteria 
phylum) (not shown). Two other changes were observed in WT mice fed curcumin-
supplemented diets: gradual decrease in Bifidobacteriales and a transient increase in 
Verrucomicrobiales at week 18. These appeared largely age-related as WT mice fed control 
diets showed similar trends, albeit without reaching statistical significance (data not shown).
The effects of dietary curcumin in AOM-induced CRC in Il10−/− mice
AOM administration to Il10−/− mice between 10th and 30th weeks of life did not 
significantly affect alpha diversity expressed either as the number of observed species (495.5 
± 39.6 and 564.5 ± 81.1, PBS vs. AOM, respectively) or as the Margalef index (56.8 ± 4.6 
and 64.7 ± 9.3, PBS vs. AOM, respectively). Taxonomic analysis of microbial composition 
clearly indicated preservative effects (pattern resembling WT/PBS mice) of curcumin on 
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major taxa, especially visible at the order level in Fig. 6B. This normalization pattern in 
response to curcumin was observed for both PBS-injected and in AOM-injected Il10−/− 
mice, and particularly for Lactobacillales and Clostridiales orders. Among the AOM/
II10−/− groups, curcumin significantly reduced the relative abundance of Clostridiales while 
increasing the abundance of Lactobacillales, Bifidobacteriales, Erisipelotrichales, 
Coriobacteriales, and the putative order YS2 from the Cyanobacteria phylum (Fig. 6B).
At the genus level however, the effects were less clear, an observation, which may explain 
the lack of clear beta diversity clustering patterns (not shown). The most significant effects 
of curcumin at this taxonomic level were observed for Lactobacillus, and several low-
abundance genera from the Firmicutes phylum (data not shown).
We next used PICRUSt to predict the differential metabolic functions represented by each 
microbial cluster. Imputed metagenomic content based on microbial profiling has been 
shown to provide a good representation of functional changes in complex, vertebrate-
associated microbial communities.40 To simplify the presentation, we compared the 
following three experimental groups: PBS/WT/0% (baseline), AOM/Il10−/−/0%, and AOM/
Il10−/−/0.5% at the time of sacrifice (week 30). 38 KEGG categories were significantly 
different by ANOVA (p≤0.05). Among those, we selected 19, which in post-hoc comparison 
(Tukey-Kramer test) showed no statistically significant difference between PBS/WT/0% and 
AOM/Il10−/−/0.5%, thus suggesting the preserving or normalizing effects of dietary 
curcumin. These 19 categories are depicted in Suppl. Fig. S3. These include pathways 
under-represented in the gut microbiome of AOM/Il10−/−/0% mice (Alzheimer’s disease, β-
lactam resistance, primary and secondary bile acid biosynthesis, amino-acid related 
enzymes, nucleotide excision repair, and ubiquinone and other terpenoid-quinone 
biosynthesis), as well as categories over-represented in the gut microbiome of AOM/
Il10−/−/0% mice (mineral absorption, other transporters, ABC transporters, styrene 
degradation, arachidonic acid metabolism, basal transcription factors, transcription factors, 
bacterial chemotaxis, bacterial motility proteins, sporulation).
DISCUSSION
Crohn’s disease and ulcerative colitis are both associated with an increased risk of 
inflammation-associated CRC, which becomes one of the most important causes for 
morbidity and mortality in IBD patients. Chemoprevention is focused on induction of 
remission and on the use of anti-inflammatory drugs targeting pathways known to be 
involved in sporadic CRC. 45 However, the probability of relapse remains high, and 
endoscopic evidence of remission does not rule out subclinical mucosal inflammation, 
which chronically may contribute the genomic instability. Moreover, inconsistent clinical 
data on chemoprevention of IBD-associated CRC suggests that there is a need for novel 
approaches. In this preclinical study with a mouse model of colitis-associated CRC,25, 46 we 
demonstrate that dietary curcumin, in a dose-dependent fashion improves survival, reduces 
tumor burden and hyperplasia, and normalizes β-catenin expression pattern in the 
colonocytes. In our study, the most effective dietary concentration of curcumin was 0.5%, 
which entirely eliminated the occurrence of macroscopic tumors. This dose roughly 
corresponds to HED of ca. 80 mg/kg/day, well within the range of well-tolerated doses 
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reported by phase I human trials.22, 23 Higher dose (1%) proved detrimental in the Il10−/− 
mouse model, an observation that was anticipated based on our previous studies with Il10−/− 
model.47
The chemopreventive effects of curcumin did not correspond with a strong suppression of 
mucosal inflammatory responses. This observation is in line with a previous study showing 
minimal effect of curcumin on inflammation in Il10−/− mice.47 Although histological score 
indicated significant improvement in the distal colon of Il10−/−/AOM mice fed 0.5% 
curcumin, this is most likely the result of diminished hyperplasia, submucosal edema, 
smooth muscle thickness, and dysplastic and neoplastic changes, which were all integral 
parts of the scoring system. Mucosal cytokine expression, a more objective measure of 
mucosal inflammatory tone, with the exception of IFNγ in the distal colon, did not indicate a 
significant reduction of inflammatory response in AOM/Il10−/− mice fed control of 
curcumin-supplemented diet (Fig. 5, Fig. S2). Therefore, we concluded that contrary to the 
results obtained from the ApcMin/+ model,48 the observed striking chemopreventive effects 
of curcumin did not correlate with significant suppression of inflammatory resposes.
Numerous in vitro studies with curcumin have demonstrated the inhibitory effects on 
intrinsic cellular mechanisms associated with neoplastic transformation, proliferation and 
apoptosis, and cell migration and invasion.16, 49 These intrinsic mechanisms likely 
contributed to the chemopreventive effects observed in our study. We investigated colonic 
microbiome as an extrinsic factor with a critical role in the pathogenesis of colitis-associated 
CRC.12, 46, 50 To this end, we determined that dietary curcumin maintained high microbial 
diversity, which otherwise declined with age between 10 and 30 weeks of age. Interestingly, 
this was associated with the expansion of Lactobacillales (represented mainly by genus 
Lactobacillus). Moreover, the relative abundance of the Lactobacillales order was decreased 
in colitic Il10−/− and in AOM/Il10−/− mice, and in both cases, dietary curcumin restored 
this order to control levels. Lactobacillus strains have been used successfully in the CRC 
prevention in animal models51–54, have been shown to exhibit significant antigenotoxicity55, 
and the Lactobacillus genus was shown to be associated with cell cycle arrest and induction 
of apoptosis in colon cancer cell lines5657. Although the results of systematic and well-
controlled clinical studies in CRC prevention are not yet available, published reports suggest 
cautious optimism. 58–60 Although our study design does not address causality, it is 
plausible that curcumin contributes to chemoprevention via expansion of the native 
Lactobacilli in the context of overall increase of colonic microbiome richness. Similar 
effects may be ascribed to increased Bifidobacteria, which have also been shown to reduce 
aberrant crypt foci in mice receiving dimethylhyrazine.61 Future experiments using 
gnotobiotic approaches would help establish the role of these microorganisms on colitis-
associated CRC.
PICRUSt analysis has been shown to provide a good representation of functional changes in 
complex communities, and may predict the results of metagenomic analyses.40,62 Analysis 
with the focus on the most abundant KEGG orthologs, which were affected by curcumin-
supplementation in AOM/Il10−/− mice showed reduced abundance of functions involved in 
transport, transcription factors, bacterial chemotaxis and bacterial motility 
proteins. 56, 57, 61, 63–67 Curcumin has been observed to inhibit bacterial motility and 
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cytotoxicity of Vibrio vulnificus68, to arrest Helicobacter pylori growth during infections69, 
as well as inhibit biofilm formation in Pseudomonas aeruginosa70. This suggests that the 
protective effect of 0.5% curcumin diet shifts the microbial composition to be more 
stationary, which may contribute to a decrease in microbial invasiveness and a decrease in 
overall disease severity. Interestingly, curcumin reduced the relative abundance of taxa 
associated with arachidonic acid (ARA) metabolism. This may represent host-associated 
response to curcumin, which is known for its ability to inhibit ARA metabolism in 
experimental CRC,71 or actual changes in the microbial community. While little is know on 
that topic, reduced ARA derived from neutrophils may lead to decreased numbers of 
bacteria utilizing ARA for growth, such as Pseudomonas.72
Although the microbial breakdown of AOM to genotoxic metabolites has been initially 
suggested to represent at least part of the mechanism of CRC induction, recent results from 
Zhen et al.73 showed that germ-free mice form significantly more and larger tumors 
compared with specific-pathogen free mice in DSS/AOM model despite the lack of early 
acute inflammation in response to DSS. This suggests that microbial AOM metabolism is 
not a prerequisite for the genotoxic effects of AOM. Therefore, it is very unlikely that the 
striking effects of curcumin on AOM-induced CRC in Il10−/− mice could be explained by 
altered AOM metabolism as a result of compositional changes in colonic microbiota.
In summary, dietary curcumin may represent an efficacious means of chemoprevention of 
inflammation-associated CRC irrespective of its direct anti-inflammatory effects. While our 
study cannot assert causality between shifts in the colonic microbial ecology (and potentially 
metabolism) and reduced (or entirely eliminated) tumor formation, we demonstrated 
efficacy of curcumin on inflammation associated colorectal cancer and normalizing effects 
of colonic microbial ecology. Curcumin may represent a promising approach to 
chemoprevention in IBD, regardless of its anti-inflammatory potential.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Experimental setup and survival
(A) Il10−/− mice and wild-type (WT) control mice were maintained until 10 weeks of age to 
allow development of colitis in the Il10−/− mice. Mice were then randomized into groups of 
6 for each curcumin diet dose: 0%, 0.05%, 0.1%, 0.5%, and 1%. Starting on week 10, mice 
received 6 weekly injections of PBS or AOM and were monitored till 30th week of life. 
Assessment of survival in PBS- (B) or AOM-injected groups (C). 16% of PBS-injected 
Il10−/− mice died in the 0% curcumin control diet group. All other PBS-injected mice in 
every group had 100% survival (A). 50% of the AOM-injected Il10−/− mice died in the 0% 
curcumin control diet group. Significant toxicity of 1% curcumin diet was documented in 
AOM-injected mice. All other AOM-injected mice had 100% survival (B). Kaplan-Meier 
curves were generated using the GraphPad Prism software (v. 5.0a).
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Figure 2. The effects of dietary curcumin on colonic hyperplasia (weight/length ratio) and 
proliferation in Il10−/−/AOM mice
(A) Upon euthanasia, colons were removed from the ileocecal junction to the anal verge at 
the end of the study and the ratio of the weight (mg) to length (cm) was measured. * 
indicates a significant (p≤0.05) difference from 0% curcumin dietary group within 
respective treatment group (bar cluster; ANOVA followed by Fisher LSD test). # indicates a 
significant (p≤0.05) difference between bars indicated by brackets (unpaired Student t-test). 
(B) Non-tumor tissue sections were labeled with anti-Ki67 antibody. (A) Representative 
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Ki67 staining in WT and Il10−/− mice treated with PBS or AOM and fed control (0%) or 
0.5% curcumin-supplemented diet (Magn. 200x). (C) Summary of the numbers of Ki67-
positive cells assessed by two investigators blinded to sample group assignment. P=0.007 
indicates statistically significant difference between WT and Il10−/− mice on control diet 
(unpaired t-test).
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Figure 3. Curcumin dose-dependently reduces tumor burden in AOM-treated Il10−/− mice
(A) Average numbers of macroscopic tumors per mouse in the proximal and distal colon 
were determined at the time of euthanasia with a stereomicroscope. Macroscopic tumors 
(shown in B) were confirmed by histological analysis by an unbiased pathologist (not 
shown). The average number of macroscopic tumors per mouse for the AOM/Il10−/− mice 
is underestimated, since two mice in this group had a high tumor burden classified as “too 
many to count” (above 10 tumors, numerous and small) and were assigned an arbitrary 
number of “10” for the purposes of calculation.
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Figure 4. Curcumin normalizes β-catenin localization in colonic tissue
(A) Representative images of β-catenin expression and cellular localization as analyzed by 
immunohistochemistry. (B) Summary of β-catenin expression with consideration to the 
number of cells per high-powered field of vision (HPF) with membrane-associated, or 
evident cytoplasmic/nuclear localization of β-catenin. * indicates statistically significant 
increase in cytoplasmic/nuclear-positive cells, while # indicates a significant decrease in 
membrane-bound-positive cells in AOM/Il10−/−/0.5% group compared to all other 
experimental groups (ANOVA followed by Fisher LSD test).
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Figure 5. The effects of dietary curcumin on colonic histology and mucosal cytokine expression
(A) Histological scoring of colonic sections from the proximal and (B) distal segments. * 
indicates a significant (p≤0.05) difference from 0% curcumin dietary group within 
respective treatment group (bar cluster; ANOVA followed by Fisher LSD test). # indicates a 
significant (p≤0.05) difference between bars indicated by brackets (unpaired Student t-test). 
(C) Representative H&E images from the distal colons of WT and Il10−/− mice treated with 
PBS or AOM and fed control (0%) or 0.5% curcumin-supplemented diet (Magn. 200x). (D) 
qPCR analysis of mucosal cytokine expression. Each sample was normalized to GAPDH 
expression and analyzed relative to PBS-injected WT mice on control diet using 2−ΔΔCt 
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method. Bars represent means and SEM. # indicates a significant (p≤0.05) difference from 
0% curcumin dietary group within respective treatment group (bar cluster; unpaired t-test). 
All others are not statistically significant. More detailed analysis which includes all 
experimental groups is presented in Suppl. Fig. S2.
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Figure 6. Taxonomic analysis of the effect of 0.5% curcumin-supplemented diet
(A) Repeated-measures non-parametric Friedman test was used to compare fecal microbial 
ecology in WT PBS-injected control mice at the time of diet switch (10 weeks), and 8 weeks 
and 16 weeks into the period of 0.5% curcumin diet (18 and 26 weeks of age). The 
taxonomic analysis (relevant abundances) at the order level was performed with 16 orders 
comprising >99.9% of OTU’s at this level. (B) Taxonomic analysis of the effect of 0.5% 
curcumin-supplemented diet in PBS- and AOM-treated Il10−/− mice. Relative order level 
microbial abundance in control WT mice (baseline) is visually compared with PBS- and 
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AOM-injected IL10−/− mice fed control (0%) or 0.5% curcumin-supplemented diets. Data 
derived from the 30th week of life (at euthanasia).
McFadden et al. Page 25
Inflamm Bowel Dis. Author manuscript; available in PMC 2016 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
